ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

439
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
bearishWuXi AppTec
11 Dec 2018 19:57

WuXi AppTec IPO Valuation: Bull/​Bear Case DCF Scenarios

WuXi AppTec Co. Ltd. (WUXI HK) is a leading global pharmaceutical R&D outsourcing service provider and the largest in Asia by revenue in 2017....

Logo
535 Views
Share
30 Nov 2018 05:53

G20 Game of Roulette:  Where Will Trump-Xi Ball Land? + 2018 Holiday Season Conviction Shorts

From conversations with investors, we believe that the market strongly expects a “positive” outcome whereby the US agrees to freeze the trade...

Logo
439 Views
Share
bearishWuXi AppTec
20 Nov 2018 20:34

WuXi AppTech IPO Trading Update: What’s up with the Poor Cash Conversion?

WuXi AppTec Co. Ltd. (WUXI HK) is a leading global pharmaceutical R&D outsourcing service provider and the largest in Asia by revenue in 2017....

Logo
907 Views
Share
bullishWuXi AppTec
19 Nov 2018 06:57

WuXi AppTech IPO Preview: Pharmed Out

WuXi AppTec Co Ltd (603259 CH) is a leading global pharmaceutical R&D outsourcing service provider and the largest in Asia by revenue in 2017....

Logo
1.1k Views
Share
28 Jun 2018 05:01

Updated Proxy Filed and Q4 Results Released

iKang Healthcare Group (ADR) (KANG US) simultaneously reported its March quarter results and filed the updated proxy for its privatization at...

Share
x